London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Methylprednisolone Sodium Succinate Injection USP, 500mg/vial and 1 gm/vial has been approved by the U.S. Food and Drug Administration (“FDA”).
9 March 2016
Product, Press Release
Methylprednisolone Sodium Succinate Injection is a corticosteroid hormone indicated to treat conditions such as arthritis, blood disorders, skin and kidney diseases and other system disorders. According to IMS Health, sales of Methylprednisolone Sodium Succinate Injection in the US market were approximately $123.5 million for the 12 months ending January 2016.